T.E.A. Study Three Days Ertapenem Versus Three Days Ampicillin- Sulbactam
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The aim of the study was to compare the activity (efficacy and safety) of Ertapenem
administered according to a short treatment for three days versus a short treatment for three
days with AS in patients with an community acquired IAI of mild to moderate severity.
Phase:
Phase 4
Details
Lead Sponsor:
University of Bologna
Collaborators:
IRCCS Azienda Ospedaliero-Universitaria di Bologna St. Orsola Hospital